Bionano Genomics, Inc.
General ticker "BNGO" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $14.1M (TTM average)
Bionano Genomics, Inc. follows the US Stock Market performance with the rate: 7.5%.
Estimated limits based on current volatility of 3.2%: low 1.12$, high 1.19$
Factors to consider:
- Earnings expected soon, date: 2026-11-10 amc
- Total employees count: 97 (-3.0%) as of 2025
- North and South America accounted for 42.7% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Limited operating history, Strategic risks and growth management, Insufficient capital, Product development failure, Market acceptance
- Current price 30.0% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.66$, 4.79$]
- 2026-12-31 to 2027-12-31 estimated range: [1.40$, 4.10$]
Financial Metrics affecting the BNGO estimates:
- Negative: with PPE of -0.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Positive: 58.04 < Shareholder equity ratio, % of 60.37 <= 68.95
- Negative: negative Operating cash flow
- Positive: Industry inventory ratio change (median), % of 0.45 <= 1.05
- Positive: -31.19 < Return on assets ratio (scaled to [-100,100]) of -26.40
- Positive: Interest expense per share per price, % of 3.59 <= 4.82
- Positive: Inventory ratio change, % of -10.93 <= -3.92
Short-term BNGO quotes
Long-term BNGO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $36.12MM | $30.78MM | $28.51MM |
| Operating Expenses | $251.36MM | $134.76MM | $61.85MM |
| Operating Income | $-215.25MM | $-103.98MM | $-33.34MM |
| Non-Operating Income | $-17.19MM | $-8.00MM | $7.01MM |
| Interest Expense | $5.12MM | $0.29MM | $0.30MM |
| R&D Expense | $54.03MM | $24.80MM | $11.37MM |
| Income(Loss) | $-232.43MM | $-111.98MM | $-26.33MM |
| Taxes | $0.06MM | $0.03MM | $0.07MM |
| Net Income(Loss)* | $-232.49MM | $-112.02MM | $-26.39MM |
| Stockholders Equity | $96.16MM | $35.38MM | $44.42MM |
| Inventory | $22.89MM | $11.12MM | $5.45MM |
| Assets | $214.40MM | $76.67MM | $73.58MM |
| Operating Cash Flow | $-125.18MM | $-68.92MM | $-16.34MM |
| Capital expenditure | $1.69MM | $0.10MM | $0.00MM |
| Investing Cash Flow | $24.16MM | $73.84MM | $-12.75MM |
| Financing Cash Flow | $113.81MM | $-13.69MM | $24.04MM |
| Earnings Per Share** | $-408.48 | $-88.13 | $-4.85 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.